![Shane Kovacs](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Shane Kovacs
Directeur/Membre du Conseil chez
Knopp Neurosciences, Inc.
Fortune : - $ au 31/05/2026
Profil
Shane William Charles Kovacs is currently Director at Knopp Neurosciences, Inc. Former positions include Director at Knopp Biosciences LLC, Managing Director-Health Care Investment Banking at Credit Suisse (Australia) Ltd. from 2002 to 2013, Managing Director at RBC Capital Markets, Inc. from 2017 to 2018, Director at PTC Therapeutics International Ltd., CFO & Head-Corporate Development at PTC Therapeutics, Inc. from 2015 to 2017, Associate at National Bank Financial, Inc., Chief Operating & Financial Officer at Olema Pharmaceuticals, Inc. from 2020 to 2026, and Chief Financial & Business Officer at BlueRock Therapeutics LP from 2018 to 2020.
Education includes undergraduate studies at Queen's University and an MBA from the University of Western Ontario.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 23/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Shane Kovacs
| Sociétés | Poste | Début |
|---|---|---|
Knopp Neurosciences, Inc.
 Knopp Neurosciences, Inc. Financial ConglomeratesFinance Operates as a shell company with no operations | Directeur/Membre du Conseil | - |
Anciens postes connus de Shane Kovacs
| Sociétés | Poste | Fin |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Directeur Financier/CFO | 30/01/2026 |
BlueRock Therapeutics LP
 BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Operates as an engineered cell therapy company which develops regenerative medicines for intractable diseases | Directeur Financier/CFO | 01/03/2020 |
RBC Capital Markets, Inc.
 RBC Capital Markets, Inc. Investment ManagersFinance Provides investment advice | Corporate Officer/Principal | 01/09/2018 |
Credit Suisse (Australia) Ltd.
 Credit Suisse (Australia) Ltd. Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | 01/05/2013 |
PTC Therapeutics International Ltd.
 PTC Therapeutics International Ltd. PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors. | Directeur/Membre du Conseil | - |
Formation de Shane Kovacs
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
37
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Financial ConglomeratesFinance Operates as a shell company with no operations | Finance |
Knopp Biosciences LLC
 Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Operates as a drug discovery and development company | Health Technology |
National Bank Financial, Inc.
 National Bank Financial, Inc. Investment ManagersFinance NBF offers the following investment vehicles for individual investors: bonds, savings bonds, retirement savings bonds, foreign currency bonds, strip bonds, Treasury bills, commercial paper, investment certificates and term deposits, MBS, preferred shares, common shares, Canadian mutual funds, US mutual funds, international mutual funds and options and derivative products. | Finance |
Queen's University
 Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Western Ontario
 University of Western Ontario Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Credit Suisse (Australia) Ltd.
Credit Suisse (Australia) Ltd. Investment Banks/BrokersFinance Provides brokerage services | Finance |
RBC Capital Markets, Inc.
RBC Capital Markets, Inc. Investment ManagersFinance Provides investment advice | Finance |
PTC Therapeutics International Ltd.
PTC Therapeutics International Ltd. PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors. | |
Olema Pharmaceuticals, Inc.
 Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
BlueRock Therapeutics LP
BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Operates as an engineered cell therapy company which develops regenerative medicines for intractable diseases | Commercial Services |
